CTI BioPharma (CTIC) Reports Completion of Enrollment in Pivotal PERSIST-1 Phase 3
Tweet Send to a Friend
CTI BioPharma (Nasdaq: CTIC) has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
